Avraham Havron - 18 Mar 2026 Form 3 Insider Report for CollPlant Biotechnologies Ltd (CLGN)

Role
Director
Signature
/s/ Avraham Havron
Issuer symbol
CLGN
Transactions as of
18 Mar 2026
Net transactions value
$0
Form type
3
Filing time
18 Mar 2026, 10:19:53 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Havron Avraham Director C/O COLLPLANT BIOTECHNOLOGIES LTD., 4 OPPENHEIMER ST, WEIZMANN SCIENCE PARK, REHOVOT, ISRAEL /s/ Avraham Havron 18 Mar 2026 0001971756

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CLGN Restricted Share Units 10,000 18 Mar 2026 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CLGN Options to Purchase Ordinary Shares 18 Mar 2026 Ordinary Shares 4,000 $4.02 Direct F1, F3
holding CLGN Options to Purchase Ordinary Shares 18 Mar 2026 Ordinary Shares 8,000 $6.39 Direct F1, F3
holding CLGN Options to Purchase Ordinary Shares 18 Mar 2026 Ordinary Shares 24,000 $6.39 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee or director in connection with the Issuer's Share Ownership and Option Plan (2010) or 2024 Share Award Plan must be registered in the name of a trustee.
F2 Of the restricted share units reported herein, 3,125 units are vested, and the remaining 6,875 units vest in eleven equal quarterly installments beginning March 25, 2026 and ending September 25, 2028, subject to the Reporting Person's continued service to the Issuer as of such vesting date.
F3 Fully vested and exercisable.
F4 22,500 options are fully vested and exercisable and the remaining 1,500 vest is May 2, 2026, subject to the Reporting Person's continued service to the Issuer as of such vesting date.